Identification of Circulating Melanoma Cells in Uveal Melanoma Patients by Dual-Marker Immunoenrichment

2014 ◽  
Vol 55 (7) ◽  
pp. 4395 ◽  
Author(s):  
Aysegül Tura ◽  
Julia Lüke ◽  
Hartmut Merz ◽  
Mihaela Reinsberg ◽  
Matthias Lüke ◽  
...  
2015 ◽  
Author(s):  
Mizue Terai ◽  
Zhaomei Mu ◽  
David Eschelman ◽  
Carin Gonsalves ◽  
Ken Kageyama ◽  
...  

2016 ◽  
Vol 29 (5) ◽  
pp. 583-589 ◽  
Author(s):  
Aysegül Tura ◽  
Hartmut Merz ◽  
Mihaela Reinsberg ◽  
Matthias Lüke ◽  
Martine J. Jager ◽  
...  

2021 ◽  
Vol 10 (8) ◽  
pp. 2618-2626
Author(s):  
Michael S. Sander ◽  
Igor Stukalin ◽  
Isabelle A. Vallerand ◽  
Siddhartha Goutam ◽  
Benjamin W. Ewanchuk ◽  
...  

2021 ◽  
Vol 22 (14) ◽  
pp. 7511
Author(s):  
Albina Fejza ◽  
Maurizio Polano ◽  
Lucrezia Camicia ◽  
Evelina Poletto ◽  
Greta Carobolante ◽  
...  

The use of immune checkpoint inhibitors has revolutionized the treatment of melanoma patients, leading to remarkable improvements in the cure. However, to ensure a safe and effective treatment, there is the need to develop markers to identify the patients that would most likely respond to the therapies. The microenvironment is gaining attention in this context, since it can regulate both the immunotherapy efficacyand angiogenesis, which is known to be affected by treatment. Here, we investigated the putative role of the ECM molecule EMILIN-2, a tumor suppressive and pro-angiogenic molecule. We verified that the EMILIN2 expression is variable among melanoma patients and is associated with the response to PD-L1 inhibitors. Consistently, in preclinical settings,the absence of EMILIN-2 is associated with higher PD-L1 expression and increased immunotherapy efficacy. We verified that EMILIN-2 modulates PD-L1 expression in melanoma cells through indirect immune-dependent mechanisms. Notably, upon PD-L1 blockage, Emilin2−/− mice displayed improved intra-tumoral vessel normalization and decreased tumor hypoxia. Finally, we provide evidence indicating that the inclusion of EMILIN2 in a number of gene expression signatures improves their predictive potential, a further indication that the analysis of this molecule may be key for the development of new markers to predict immunotherapy efficacy.


2000 ◽  
Vol 10 (1) ◽  
pp. 36-39 ◽  
Author(s):  
E. Tóth-Molnár ◽  
H. Hammer ◽  
J. Oláh

2006 ◽  
Vol 83 (1) ◽  
pp. 176-182 ◽  
Author(s):  
Haochuan Li ◽  
Jerry Y. Niederkorn ◽  
Sudha Neelam ◽  
Hassan Alizadeh

2015 ◽  
Vol 1 (3) ◽  
pp. 170-181 ◽  
Author(s):  
Wietske van der Ent ◽  
Claudia Burrello ◽  
Mark J. de Lange ◽  
Pieter A. van der Velden ◽  
Aart G. Jochemsen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document